Figure 1.

Cell-based DQ-BSA HCI assay identifies fluoxetine (FLX) as a compound hit in MPS-IIIA MEFs

(A) Plot representing the Pearson correlation coefficient of the 3 replicas of the 4 Prestwick sub-libraries screened. (B) Plot representing the results of the screening. The y axis shows the DQ-BSA spots per cell values ±SEMs of the hit compounds obtained from the screening, compared to the untreated cells value (DMSO, median of the 4 sub-libraries), and the positive control value (Torin-1, median of the 4 sub-libraries). ANOVA test, ∗∗p < 0.01 versus DMSO; ∗∗∗p < 0.001 versus DMSO. (C) Hit compounds classification. The pie chart shows the drug class distribution of the hit compounds in percentage. (D) FLX re-testing in dose-response format. Dose-response curves of DQ-BSA spots per cell and viability (nuclei count) ± SEMs with relative EC₅₀ and IC₅₀ values, derived from the treatment of MPS-IIIA MEFs with FLX at scalar doses (from 30 to 0, 1 μM) of n > 100 cells from 2 independent experiments. The HCI images of the DQ-BSA spots are representative of the treatment with FLX at 3 μM compared to the untreated cells.